RAD51 and lung carcinoma: Moreover, an increasing number of researchers have suggested that targeting RAD51 using specific antisense oligonucleotides or specific chemotherapeutic drugs or antibodies was a promising strategy to help lung cancer patients to reduce the chance for acquiring resistance to gefitinib, cisplatin, mitomycin C (MMC) and other therapeutic agents [21].